Pharmaceutical composition containing ezrin mutated on tyrosin 353

Abstract

The invention relates to a pharmaceutical composition containing an effective amount of ezrin mutated on tyrosine 353, or a functional fragment or derivative thereof, in association with a pharmaceutically acceptable carrier, for use preferably in the prevention and/or treatment of tumors.

What is claimed is:  
     
         1 . An isolated polypeptide which exhibits an ability of an ezrin protein mutated on tyrosine 353 (Y353 ezrin mutant) to induce apoptosis, and has an amino acid sequence comprising an amino acid sequence of the Y353 ezrin mutant and further comprising at least seven contiguous amino acids of the Y353 ezrin mutant from residue 350 to residue 356 of SEQ IQ No: 1.  
     
     
         2 . The polypeptide according to  claim 1 , wherein the polypeptide is an ezrin protein having the amino acid sequence set forth in SEQ ID No: 1, mutated on tyrosine 353.  
     
     
         3 . The polypeptide according to  claim 1 , wherein the polypeptide had the amino acid sequence set forth in SEQ ID No: 1 mutated on tyrosine 353 and wherein a hydrophobic amino acid flanking residues 350-356 of SEQ ID No: 1 is replaced by another hydrophobic amino acid.  
     
     
         4 . The polypeptide according to  claim 1 , wherein the polypeptide has the amino acid sequence set forth in SEQ ID No: 1 mutated on tyrosine 353 and wherein a polar amino acid flanking residues 350-356 of SEQ ID No:1 is replaced by another polar amino acid.  
     
     
         5 . The polypeptide according to  claim 1 , wherein the polypeptide has the amino acid sequence set forth in SEQ ID No: 1 mutated on tyrosine 353 and wherein a basic amino acid flanking residues 350-356 of SEQ ID No: 1 is replaced by another basic amino acid.  
     
     
         6 . The polypeptide according to  claim 1 , wherein the polypeptide has the amino acid sequence set forth in SEQ ID No: 1 mutated on tyrosine 353 and wherein an acidic amino acid flanking residues 350-356 of SEQ ID No: 1 is replaced by another acidic amino acid.  
     
     
         7 . The polypeptide according to  claim 1 , wherein the polypeptide had the amino acid sequence set forth in SEQ ID No: 1 mutated on tyrosine 353 and wherein a proline residue flanking residues 350-356 of SEQ ID No: 1 mutated on tyrosine 353 and wherein a proline residue flanking residues 350-356 of SEQ ID No: 1 is replaced by 4-hydroxyproline.  
     
     
         8 . The polypeptide according to  claim 1 , wherein the polypeptide has the amino acid sequence set forth in SEQ ID No: 1 mutated on tyrosine 353 and wherein an histidine residue flanking residues 350-356 of SEQ ID No: 1 is replaced by N-imidazole benzylhistidine.  
     
     
         9 . The polypeptide according to  claim 1 , wherein tyrosine 353 is mutated into a phenylalanine residue.  
     
     
         10 . A pharmaceutical composition comprising the polypeptide according to  claim 1 , in association with a pharmaceutically acceptable carrier.  
     
     
         11 . A method for inducing apoptosis in tumor cells, which method comprises administering to the tumor cells an effective amount of the composition according to  claim 10  so as to induce apoptosis in the tumor cells.  
     
     
         12 . The method according to  claim 11 , wherein the tumor cells comprise metastatic cells.  
     
     
         13 . The method according to  claim 11 , wherein the composition is administered to a patient that suffers from a tumor.